Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Top Cited Papers
- 1 March 2000
- journal article
- biology of-neoplasia
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (5) , 1135
- https://doi.org/10.1200/jco.2000.18.5.1135
Abstract
Tumor progression is a complex, multistage process by which a normal cell undergoes genetic changes that result in phenotypic alterations and the acquisition of the ability to spread and colonize distant sites in the body. Although many factors regulate malignant tumor growth and spread, interactions between a tumor and its surrounding microenvironment result in the production of important protein products that are crucial to each step of tumor progression. The matrix metalloproteinases (MMPs) are a family of degradative enzymes with clear links to malignancy. These enzymes are associated with tumor cell invasion of the basement membrane and stroma, blood vessel penetration, and metastasis. They have more recently been implicated in primary and metastatic tumor growth and angiogenesis, and they may even have a role in tumor promotion. This review outlines our current understanding of the MMP family, including the association of particular MMPs with malignant phenotypes and the role of MMPs in specific steps of the metastatic cascade. As scientific understanding of the MMPs has advanced, therapeutic strategies that capitalize on blocking the enzymes have rapidly developed. The preclinical and clinical evolution of the synthetic MMP inhibitors (MMPIs) is also examined, with the discussion encompassing important methodologic issues associated with determining clinical efficacy of MMPIs and other novel therapeutic agents.Keywords
This publication has 91 references indexed in Scilit:
- TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3FEBS Letters, 1998
- Head and Neck CancerAnnals of Oncology, 1998
- Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancerSurgical Oncology, 1995
- Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase aInternational Journal of Cancer, 1995
- Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic MiceJNCI Journal of the National Cancer Institute, 1995
- ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions.The Journal of cell biology, 1995
- Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancerInternational Journal of Cancer, 1995
- Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitorInternational Journal of Cancer, 1994
- Metastatic potential correlates with enzymatic degradation of basement membrane collagenNature, 1980